NeuroSense Therapeutics Ltd (NRSN)

[crudeoil24]

NeuroSense Therapeutics Sees Positive Trial Results for TDP-43 Alzheimer's Treatment
9:03 am ET January 19, 2023 (Dow Jones) Print

By Chris Wack


NeuroSense Therapeutics Ltd. said it saw positive final results from a biomarker study conducted to evaluate the potential of NeuroSense's combination platform therapy for the treatment of Alzheimer's disease.

The company said preliminary results from the study showed that TDP-43, a novel biomarker, was elevated in Alzheimer's disease patients compared with a healthy control group.

Based on these preliminary results, NeuroSense said it expanded the study with a larger healthy control group to further validate the results.

NeuroSense's platform combination therapy technology has already shown a statistically significant reduction of TDP-43 in a Phase 2a clinical trial biomarker study in another neurodegenerative disease, amyotrophic lateral sclerosis, and is now being evaluated in a Phase 2b ALS double-blind clinical trial.

The company plans to start a Phase 2 double-blind proof-of-concept study in Alzheimer's disease in the first half of 2023.

NRSN